Investor Diligence and Decision Support
We support VC/CVC teams, Private Equity, Hedge Funds, and other investors with decision-grade intelligence in BioPharma, HealthTech, and AI-enabled healthcare. From fast diligence to ongoing monitoring, we help you validate assumptions, surface risks early, and act with confidence.
From identifying emerging trends and hidden risks to supporting diligence and portfolio decisions, we deliver concise, actionable recommendations that create an edge.
Our work commonly includes:
- Landscape + diligence (science, commercial, competitive dynamics)
- Company/asset profile (TAM, segmentation, growth drivers, value proposition)
- Opportunity/risk assessment (red flags, catalysts, scenarios, mitigations)
- Custom research aligned to your thesis and timelines (deal-specific questions, thesis validation, monitoring)
- Primary intelligence (targeted KOL and stakeholder interviews to resolve the specific uncertainties in your thesis)
Typical engagement modes:
- Diligence Sprint (5–10 business days)
- Monthly monitoring and brief updates
- Decision workshops and AI-powered wargaming (via LucidWargames) to stress-test theses and quantify scenario risk
Don’t forget to check out our Lucid Diligence Briefs, delivering 60-second theses, questions to ask, red flags and catalysts to watch, linked to trending news.
Want to move faster on your next decision? Contact: info@lqventures.com
April 21, 2026
Endocrinology Today—April 21, 2026
April 21, 2026
Obesity Today—April 21, 2026
April 20, 2026
Oncology Today—April 20, 2026
April 20, 2026
Hematology Today—April 20, 2026
April 20, 2026
AI in Healthcare and Digital Health Today—April 20, 2026
April 20, 2026
Lucid Diligence Brief: 10x Genomics launches Atera Platform
April 19, 2026
Lucid Diligence Brief: MeiraGTx re-acquires bota-vec rights from J&J
April 17, 2026
Respiratory Today—April 17, 2026
April 17, 2026
Vaccines Today—April 17, 2026
April 17, 2026